Amgen (AMGN) Analyst Insights: Meritide Trials, Biosimilars, and Rare Disease Momentum

Amgen (AMGN) reported Q4 broad-based sales growth, with 13 products posting double-digit sales and 14 exceeding $1B in annual sales. CEO Robert Bradway and EVP Murdo Gordon attributed gains to expanded patient reach, new indications, and access programs like Amgen Now, with strong momentum in biosimilars, rare disease, and oncology. Analysts are closely watching Meritide’s late-stage enrollment and regulatory milestones; the impact of biosimilar launches on legacy sales; and adoption of new indications and geographies in rare disease and oncology. Management will also be tested on manufacturing scale-up and execution of pipeline launches. AMGN closed at $376.15, up from $338.59, reflecting broader market strength. Key dates: February 10, 2026 (analysis based on earnings call and stock price as of publication).